"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 5 | 4 | 9 |
| 2018 | 11 | 4 | 15 |
| 2019 | 5 | 1 | 6 |
| 2020 | 3 | 2 | 5 |
| 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Increasing Short- and Long-Term Buprenorphine Treatment Capacity: Providing Waiver Training for Medical Students. Acad Med. 2022 02 01; 97(2):182-187.
-
Low-Threshold Buprenorphine via Community Partnerships and Telemedicine-Case Reports of Expanding Access to Addiction Treatment During COVID-19. J Addict Med. 2022 Jan-Feb 01; 16(1):e56-e58.
-
Pregnant Patients Using Opioids: Treatment Access Barriers in the Age of COVID-19. J Addict Med. 2022 Jan-Feb 01; 16(1):e44-e47.
-
A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic. J Addict Med. 2022 Jan-Feb 01; 16(1):e40-e43.
-
Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. J Addict Med. 2021 Nov-Dec 01; 15(6):448-451.
-
Barriers and Facilitators to Buprenorphine Prescribing for Opioid Use Disorder in the Veterans Health Administration During COVID-19. J Addict Med. 2021 Sep-Oct 01; 15(5):439-440.
-
Adapting a Low-threshold Buprenorphine Program for Vulnerable Populations During the COVID-19 Pandemic. J Addict Med. 2021 Sep-Oct 01; 15(5):364-369.
-
Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020. J Gen Intern Med. 2021 12; 36(12):3915-3917.
-
The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review. Subst Abuse Treat Prev Policy. 2021 08 09; 16(1):60.
-
Long-acting buprenorphine injectables: Opportunity to improve opioid use disorder treatment among rural populations. Prev Med. 2021 11; 152(Pt 2):106756.